Neuronetics Inc
$ 1.33
4.72%
04 Mar - close price
- Market Cap 91,086,000 USD
- Current Price $ 1.33
- High / Low $ 1.40 / 1.27
- Stock P/E N/A
- Book Value 0.40
- EPS -0.83
- Next Earning Report 2026-03-17
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.21 %
- ROE -2.19 %
- 52 Week High 5.34
- 52 Week Low 1.17
About
Neuronetics, Inc., a commercial-stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States and internationally. The company is headquartered in Malvern, Pennsylvania.
Analyst Target Price
$6.50
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-04 | 2025-08-05 | 2025-05-05 | 2025-03-04 | 2024-11-05 | 2024-08-12 | 2024-05-07 | 2024-03-05 | 2023-11-07 | 2023-08-08 | 2023-05-09 | 2023-03-07 |
| Reported EPS | -0.13 | -0.15 | -0.2062 | -0.33 | -0.4408 | -0.33 | -0.27 | -0.19 | -0.33 | -0.17 | -0.38 | -0.3 |
| Estimated EPS | -0.13 | -0.08 | -0.1167 | -0.24 | -0.23 | -0.27 | -0.31 | -0.26 | -0.31 | -0.35 | -0.39 | -0.38 |
| Surprise | 0 | -0.07 | -0.0895 | -0.09 | -0.2108 | -0.06 | 0.04 | 0.07 | -0.02 | 0.18 | 0.01 | 0.08 |
| Surprise Percentage | 0% | -87.5% | -76.6924% | -37.5% | -91.6522% | -22.2222% | 12.9032% | 26.9231% | -6.4516% | 51.4286% | 2.5641% | 21.0526% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-17 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.12 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: STIM
2026-03-04 19:52:43
STIM (Neuronetics, Inc.) filed a Form 144, indicating proposed sales of common stock by insider William A. Macan. The filing details recent open-market dispositions on February 10, 12, and 26, 2026, and notes restricted stock vesting as the source of securities, labeled as compensation. Fidelity Brokerage Services LLC is named as the broker involved.
2026-03-03 13:51:39
Neuronetics, Inc. announced its plan to release fourth-quarter 2025 financial and operating results before market open on Tuesday, March 17, 2026. The company will host a conference call at 8:30 a.m. Eastern Time on the same day to discuss these results. Neuronetics specializes in medical technology, including its NeuroStar Advanced Therapy, a non-drug, noninvasive treatment for neurohealth conditions.
2026-03-02 21:53:12
Neuronetics Inc. (STIM) has entered into a Second Amendment to its Registration Rights Agreement with Madryn Asset Management. This amendment updates the process for potential future resale registrations of Neuronetics shares held by Madryn and includes a commitment from Madryn to vote their shares in line with the Board of Directors' recommendations at the 2026 annual meeting. The agreement specifies that Neuronetics must file a registration statement for Madryn's Registrable Securities within five business days after filing its 2025 Form 10-K, provided a Shelf Notice is received.
2026-02-28 07:53:13
Neuronetics, Inc. EVP, CLO, and CS William Andrew Macan sold 3,427 shares of common stock at a weighted average price of $1.35 per share. This was a non-discretionary transaction to cover tax withholding obligations associated with the vesting of a restricted stock unit award. Following the sale, Macan directly holds 880,134 shares of Neuronetics common stock.
2026-02-28 07:53:12
The article provides a technical analysis and stock price forecast for Neuronetics Inc (STIM), indicating a "Strong Sell" consensus based on various technical indicators. Key metrics like MACD, moving averages (20-day, 60-day, 200-day), and support/resistance levels suggest continued bearish sentiment for the stock, despite a neutral RSI.
2026-02-27 23:52:37
Neuronetics CEO Keith Sullivan sold 8,452 shares of the company’s stock on February 26th at an average price of $1.35, totaling $11,410.20. Following the sale, Sullivan now owns 1,524,713 shares, representing a 0.55% reduction in his position. The company's stock currently trades at $1.34 with a market capitalization of $91.77 million and a consensus analyst rating of "Hold" with a $7.00 price target.
